Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eylea in DME previously treated with ranibizumab or bevacizumab
NCT02559180Phase 4Completed
- Sponsor
- Rishi Singh
- Start
- Oct 2015
- Primary completion
- Dec 2020
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label trial of aflibercept in diabetic macular edema (DME), sponsored by Rishi Singh. Primary endpoints: Best Corrected Visual Acuity at 12 months and Central Foveal Thickness at 12 months. Started Oct 2015; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02559180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02559180.